ATSENA THERAPEUTICS

atsena-therapeutics-logo

Atsena Therapeutics is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness. Atsena has an ongoing Phase I/II clinical trial evaluating a potential therapy for one of the most common causes of blindness in children. Its pipeline of clinical and preclinical assets is powered by adeno-associated virus (AAV) technology tailored to overcome the hurdles presented by inherited retinal disease, and its approach is guided by the specific needs of each patient condition.

#SimilarOrganizations #People #Financial #Event #Website #More

ATSENA THERAPEUTICS

Social Links:

Industry:
Biotechnology Health Care Therapeutics

Founded:
2019-01-01

Address:
Durham, North Carolina, United States

Country:
United States

Website Url:
http://www.atsenatx.com

Total Employee:
11+

Status:
Active

Email Addresses:
info@atsenatx.com

Total Funding:
87.62 M USD

Technology used in webpage:
Person Schema Gravatar Profiles U.S. Server Location Vimeo


Similar Organizations

beacon-therapeutics-logo

Beacon Therapeutics

Beacon Therapeutics is an ophthalmic gene therapy company to treat blinding retinal illnesses and restore and enhance eyesight.

cedilla-therapeutics-logo

Cedilla Therapeutics

Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.

interline-therapeutics-logo

Interline Therapeutics

Interline Therapeutics is a drug discovery platform that enables the company to map and correct dysfunctional protein communities.

passage-bio-logo

Passage Bio

Passage Bio is a fully integrated gene therapy company developing therapies for the treatment of monogenic central nervous system diseases.


Current Advisors List

sarah-bhagat_image

Sarah Bhagat Advisor @ Atsena Therapeutics
Advisor
2022-08-01

sarah-bhagat_image

Sarah Bhagat Board Member @ Atsena Therapeutics
Board_member
2020-12-01

jacqueline-grant_image

Jacqueline Grant Board Member @ Atsena Therapeutics
Board_member
2020-12-01

jason-lettmann_image

Jason Lettmann Board Member @ Atsena Therapeutics
Board_member
2020-12-01

Current Employees Featured

sanford-boye_image

Sanford Boye
Sanford Boye Founder and Chief Technology Officer @ Atsena Therapeutics
Founder and Chief Technology Officer
2020-04-01

linda-b-couto_image

Linda B. Couto
Linda B. Couto Chief Scientific Officer @ Atsena Therapeutics
Chief Scientific Officer
2021-08-01

patrick-ritschel_image

Patrick Ritschel
Patrick Ritschel Chief Executive Officer @ Atsena Therapeutics
Chief Executive Officer
2020-01-01

shannon-boye_image

Shannon Boye
Shannon Boye Founder and Director @ Atsena Therapeutics
Founder and Director
2020-04-01

elisabeth-leiderman_image

Elisabeth Leiderman
Elisabeth Leiderman Chief Financial Officer & Chief Business Officer @ Atsena Therapeutics
Chief Financial Officer & Chief Business Officer
2022-11-01

kenji-fujita_image

Kenji Fujita
Kenji Fujita Chief Medical Officer @ Atsena Therapeutics
Chief Medical Officer
2021-06-01

Founder


sanford-boye_image

Sanford Boye

shannon-boye_image

Shannon Boye

Investors List

hatteras-venture-partners_image

Hatteras Venture Partners

Hatteras Venture Partners investment in Series A - Atsena Therapeutics

manning-family-foundation_image

Manning Family Foundation

Manning Family Foundation investment in Series A - Atsena Therapeutics

lightstone-ventures_image

Lightstone Ventures

Lightstone Ventures investment in Series A - Atsena Therapeutics

retinal-degeneration-fund_image

Retinal Degeneration Fund

Retinal Degeneration Fund investment in Series A - Atsena Therapeutics

sofinnova-ventures_image

Sofinnova Investments

Sofinnova Investments investment in Series A - Atsena Therapeutics

abingworth-management_image

Abingworth

Abingworth investment in Series A - Atsena Therapeutics

osage-university-partners_image

OUP (Osage University Partners)

OUP (Osage University Partners) investment in Series A - Atsena Therapeutics

university-of-florida_image

University of Florida

University of Florida investment in Series A - Atsena Therapeutics

pbm-capital-group_image

PBM Capital Group

PBM Capital Group investment in Series A - Atsena Therapeutics

osage-university-partners_image

OUP (Osage University Partners)

OUP (Osage University Partners) investment in Series A - Atsena Therapeutics

Official Site Inspections

http://www.atsenatx.com Semrush global rank: 8.1 M Semrush visits lastest month: 650

  • Host name: 141.193.213.21
  • IP address: 141.193.213.21
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "Atsena Therapeutics"

Atsena Therapeutics

Nov 13, 2024 ATSENA THERAPEUTICS is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness.See details»

Compassionate Use and Expanded Access - Atsena Therapeutics

Atsena Therapeutics is evaluating investigational gene therapies in clinical trials for patients with inherited retinal diseases who have limited or no treatment options.See details»

Atsena Therapeutics – Company Overview

Atsena Therapeutics is a clinical-stage gene therapy company, focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness.See details»

Atsena Therapeutics - Crunchbase Company Profile

Atsena Therapeutics is a clinical-stage gene therapy company that develops novel treatments for inherited forms of blindness. View contacts for Atsena Therapeutics to access new leads and connect with decision-makers.See details»

Nippon Shinyaku and Atsena Therapeutics enter into an Exclusive ...

Nov 13, 2024 Based on Nippon Shinyaku’s business philosophy, “Helping people lead healthier, happier lives,” we aim to be an organization trusted by the community through creating unique …See details»

Nippon Shinyaku and Atsena Therapeutics enter into an

Nov 13, 2024 Based on Nippon Shinyaku’s business philosophy, “Helping people lead healthier, happier lives,” we aim to be an organization trusted by the community through creating unique …See details»

Nippon Shinyaku and Atsena Therapeutics enter into an Exclusive ...

Nov 13, 2024 Based on Nippon Shinyaku’s business philosophy, “Helping people lead healthier, happier lives,” we aim to be an organization trusted by the community through creating unique …See details»

Atsena Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...

Explore Atsena Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 2 clinical trials, 30 news, and 1 literature, Disease Domain:Nervous System Diseases, …See details»

Atsena Therapeutics to Present ATSN-201 Safety and Efficacy Data …

DURHAM, N.C., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to …See details»

ATSN-101 - Drug Targets, Indications, Patents - Synapse

DURHAM, N.C., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to …See details»

Atsena Therapeutics Receives Orphan Drug Designation from

Sep 18, 2024 Marks second FDA designation for ATSN-201, which previously received Rare Pediatric Disease designation. DURHAM, N.C., Sept. 17, 2024 (GLOBE NEWSWIRE) -- …See details»

Atsena Therapeutics Receives Orphan Drug Designation from

Sep 17, 2024 info@atsenatx.com. Market Updates. More Market Updates What’s Happening in the Markets This Week. Frank Lee Jul 20, 2023. Worst-Performing Stock ETFs of the Quarter. …See details»

News - Retinal Degeneration) Fund

October, 03 2022 • Articles. Atsena Therapeutics Announces Positive Results from Phase I/II Clinical Trial of ATSN-101 for the Treatment of GUCY2D-associated Leber Congenital …See details»

Atsena Therapeutics Receives FDA Clearance of IND Application …

ATSN-201 leverages AAV capsid that spreads laterally beyond subretinal injection site to facilitate safe delivery of RS1 to photoreceptors in the central retina/fovea Initiation of Phase I/II ...See details»

Atsena Therapeutics – Atsena Therapeutics Announces Positive …

May 1, 2024 For more information, please visit https://atsenatx.com. Media Contact: Tony Plohoros 6 Degrees (908) 591-2839 [email protected] Business Contact: [email protected] …See details»

News - Retinal Degeneration) Fund

November, 14 2023 • Articles. Atsena Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ATSN-101 Gene Therapy for GUCY2D-associated …See details»

Atsena Therapeutics – Nippon Shinyaku and Atsena Therapeutics …

Nov 13, 2024 Atsena Therapeutics is a clinical-stage gene therapy company developing best-in-class treatments for the reversal or prevention of blindness from inherited retinal diseases.See details»

Atsena Therapeutics – Atsena Therapeutics Receives Orphan Drug ...

Sep 17, 2024 Atsena Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ATSN-201 Gene Therapy to Treat X-linked Retinoschisis. Marks second FDA designation for …See details»

Nippon Shinyaku and Atsena Therapeutics enter into an Exclusive ...

Nov 13, 2024 KYOTO, Japan and DURHAM, N.C., Nov. 13, 2024 (GLOBE NEWSWIRE) — Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; Headquarters: Kyoto; President, Toru Nakai) …See details»

Nippon Shinyaku and Atsena Therapeutics enter into an Exclusive ...

Nov 13, 2024 Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; Headquarters: Kyoto; President, Toru Nakai) and Atsena Therapeutics, Inc. (Atsena; Headquarters: Durham, North Carolina, …See details»

linkstock.net © 2022. All rights reserved